Interrad Medical Touts Positive SecurAcath Study Results

Interrad Medical Inc.’s method for securing catheters is more effective than standard adhesive use, a new clinical study has concluded.

Published in JAMA Pediatrics, the multi-center, randomized controlled trial—“Securement to prevent non-cuffed central venous catheter dislodgement in pediatrics The SECURED superiority randomized clinical trial”—was undertaken in partnership with The Queensland Children’s Hospital, The University of Queensland, and researchers of the Alliance for Vascular Access Teaching and Research (AVATAR), Griffith University, Brisbane, Australia. The study compared the dislodgement rate (partial or complete) of non-cuffed CVCs secured with SecurAcath to the market-leading adhesive securement device. A total of 307 pediatric patients were randomized—153 to SecurAcath and 154 to an adhesive device.
 
The results showed a 4.4-fold decreased catheter dislodgement in the SecurAcath group (5.2%) compared to adhesive device group (22.7%).

“Catheter dislodgement is a major clinical problem for our pediatric patients, with potentially life-threatening consequences. The results of this study clearly show SecurAcath reduces dislodgement and saves money, therefore, SecurAcath should be used preferentially over adhesive device securement,” said Tricia Kleidon, R.N., MNursePrac, lead study author.
 
Seven secondary outcomes also highly favored SecurAcath as well. Chief among these, complications reported during catheter dwell were 39% lower for SecurAcath most notably, central line associated bloodstream infections (CLABSI) which were 50% lower in the SecurAcath group. The study’s comparative cost savings analysis showed the SecurAcath device overall saved AU $36.60 ($24.54) with every use.
 
“We are extremely pleased with the very favorable results of this important comparative study,” Interrad Medical President/CEO Joe Goldberger stated. “This superiority evidence provides the strongest support to date that SecurAcath will become the new global standard for catheter securement.”
 
SecurAcath is reportedly the world’s only subcutaneous catheter securement device. One SecurAcath lasts the life of the line and can significantly reduce the risk of catheter-related infections, dramatically decrease catheter dislodgement and migration, and decrease catheter replacement costs resulting in significant cost savings, according to study data. SecurAcath has overwhelmingly more positive clinical evidence and independent clinical guidance than any other catheter securement device in the world, with 27 peer-reviewed scientific publications consistently concluding clinical and economic benefits, according to Interrad Medical. 

SecurAcath has small, blunt, flexible securement feet that are placed just beneath the skin; they help stabilize the catheter at the insertion site. The device is designed to secure a catheter for the entire duration of therapy, eliminate catheter movement or dislodgement, and prevent therapy interruption. Since it does not need to be changed out, SecurAcath expedites dressing changes. 

Plymouth, Minn.-based Interrad Medical develops, manufactures, and markets medical devices designed for minimally-invasive medical procedures. Its lead product, the SecurAcath Subcutaneous Anchor Securement System (SASS), is a new method for catheter securement that does not require sutures or adhesives.